Today: 22 March 2026
Subscribe
Browse Category

NASDAQ:SPRE 4 January 2026 - 23 February 2026

Spyre Therapeutics stock dips premarket after Friday surge as $500 million shelf hangs over shares

Spyre Therapeutics stock dips premarket after Friday surge as $500 million shelf hangs over shares

Spyre Therapeutics shares dropped 4.2% to $41.38 in premarket trading Monday after a 14.3% surge Friday. The move follows Thursday’s filing of a $500 million shelf registration, raising dilution concerns. Investors are watching for initial Phase 2 ulcerative colitis data, expected in the second quarter of 2026. Spyre ended 2025 with $757 million in cash and marketable securities.
23 February 2026
·
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Spyre Therapeutics shares dropped 6.6% to $30.58 on Friday, closing near session lows after about 889,000 shares traded. The move followed comments from Philadelphia Fed President Anna Paulson signaling rate cuts may be delayed. Spyre remains below its 52-week high of $34.49, with traders eyeing whether the stock can hold above $30 at Monday’s open. No significant company news has been released since the last quarterly update.
4 January 2026
·

Stock Market Today

  • Australia Shares Expected to Decline at Open, New Zealand Markets Fall
    March 22, 2026, 6:45 PM EDT. Australian shares are forecast to open lower amid regional market pressures, with New Zealand's market also declining. Investors remain cautious as global economic indicators weigh on sentiment. The Australian Securities Exchange (ASX) is set to follow the downtrend seen in other Asia-Pacific markets, reflecting concerns over growth prospects. New Zealand's benchmark index has retreated, pressured by similar factors. Traders are monitoring external influences, including commodity prices and currency fluctuations, ahead of key economic data releases. The outlook remains uncertain as markets adjust to ongoing geopolitical and economic developments.
Go toTop